Related Experiment Videos
Steroid 5alpha-reductase inhibitors
Eugenio Flores1, Eugene Bratoeff, Marisa Cabeza
1National University Mexico D.F. and Metropolitan University Mexico D.F., Mexico. eugene@servidor.unam.mx
Mini Reviews in Medicinal Chemistry
|February 7, 2003
Summary
New steroidal compounds were synthesized to inhibit 5alpha-reductase, an enzyme linked to androgen-dependent diseases. Trienone derivatives demonstrated superior inhibitory activity compared to dienones, suggesting a new therapeutic strategy.
Area of Science:
- Medicinal Chemistry
- Endocrinology
- Pharmacology
Background:
- Androgen-dependent diseases like prostate cancer and alopecia are linked to dihydrotestosterone (DHT).
- 5alpha-reductase enzyme metabolizes testosterone to DHT, making it a therapeutic target.
- Existing drugs like finasteride inhibit 5alpha-reductase, alleviating symptoms of benign prostatic hyperplasia.
Purpose of the Study:
- To synthesize novel steroidal compounds based on the progesterone skeleton.
- To evaluate the 5alpha-reductase inhibitory activity of these new compounds.
- To explore new antiandrogenic drug candidates for androgen-dependent conditions.
Main Methods:
- Synthesis of various 16beta-substituted pregnadiene and pregnatriene dione derivatives.
- In vitro and in vivo evaluation of 5alpha-reductase inhibition using multiple biological models.
- Assessment of steroid metabolism and effects on androgen-sensitive tissues.
Main Results:
- All synthesized trienone derivatives exhibited higher 5alpha-reductase inhibitory activity than their corresponding dienone counterparts.
- The enhanced activity of trienones is attributed to their more coplanar structure, facilitating faster reaction with the enzyme.
- Compounds 30, 31, and 43-46 were identified as potent inhibitors.
Conclusions:
- Novel steroidal trienones are effective inhibitors of 5alpha-reductase.
- These compounds represent promising candidates for the development of new antiandrogenic therapies.
- The mechanism of inhibition likely involves irreversible Michael addition to the enzyme's active site.